On this episode, broadening of immune responses to SARS-CoV-2 after mRNA vaccine booster to ChAdOx1 nCoV-19, five-fold underestimation of the number of cases in the US during the first six months of the pandemic, and a monoclonal antibody that broadly neutralizes many different sarbecoviruses.
Hosts: Vincent Racaniello and Amy Rosenfeld
Click arrow to play
Download TWiV 782 (38 MB .mp3, 63 min)
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Immune responses after heterologous COVID-19 vaccine boost (Nat Med) 4:58
- Undiagnosed SARS-CoV-2 infections in US (Sci Transl Med) 21:28
- Broadly neutralizing sarbecovirus antibody (Nature) 35:53
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your virology questions and comments to email@example.com
Why didn’t we test more people early in the pandemic? Because test kits were scarce.
Which “Ebola” paper is Amy refering to?
Comment on the discussion of the SARS-CoV-2 RBD vaccine candidate that originated at Baylor (from Peter Hotez). Amy mentioned she thought it “didn’t work”. In fact, this candidate is still in development by Biological E (India) and received funding from CEPI at the end of last year:
It does remain to be seen how this RBD candidate will compare with constructs expressing full-length spike, but given the continuing high demand for vaccines in low- and middle-income countries, it still has the potential to play an important role since CEPI and Biological E are committed to making it available at an affordable price.